Table 6:
Clinical characteristics and performance of those participants who demonstrated a significant difference between the plural-s and possessive ‘s
| Participant | Group | Variant | MorGen | -s | ’s | Δ |
|---|---|---|---|---|---|---|
| NBN | PPA | lvPPA | 86.6 | 100.0 | 82.4 | 17.7* |
| LST | PPA | lvPPA | 94.9 | 100.0 | 82.4 | 17.7* |
| WSH | PPA | lvPPA | 90.5 | 96.8 | 76.5 | 20.3* |
| SAD | PPA | lvPPA | 61.6 | 67.7 | 0.0 | 67.7** |
| JBK | PPA | lvPPA | 63.6 | 87.1 | 0.0 | 87.1** |
| MBN | PPA | lvPPA | 82.4 | 93.6 | 5.9 | 87.7** |
| MAT | PPA | lvPPA | 56.2 | 93.6 | 0.0 | 93.6** |
| KGE | PPA | lvPPA | 78.9 | 100.0 | 0.0 | 100.0** |
| RLR | PPA | nfavPPA | 96.6 | 100.0 | 76.5 | 23.5* |
| WTN | PPA | nfavPPA | 67.0 | 100.0 | 0.0 | 100.0** |
| JSR | PPA | svPPA | 73.5 | 100.0 | 76.5 | 23.5* |
| MJE | PPA | svPPA | 7.6 | 48.4 | 0.0 | 48.4** |
| MSH | PPA | svPPA | 45.7 | 74.2 | 17.7 | 56.6** |
| AJN | PPA | svPPA | 60.3 | 93.6 | 29.4 | 64.1** |
| MHN | PPA | svPPA | 59.7 | 80.7 | 0.0 | 80.7** |
| TFD | PPA | svPPA | 78.5 | 83.9 | 0.0 | 83.9** |
| JSE | PPA | svPPA | 75.5 | 93.6 | 0.0 | 93.6** |
| WGH | PPA | svPPA | 83.2 | 96.8 | 0.0 | 96.8** |
| BOY | PPA | unclassifiable PPA | 64.5 | 93.6 | 41.2 | 52.4** |
| LGN | PPA | unclassifiable PPA | 70.7 | 96.8 | 29.4 | 67.4** |
| LST | Acute | None | 91.6 | 100.0 | 70.6 | 29.4** |
| CLA | Acute | None | 80.0 | 96.8 | 58.8 | 38.0** |
| GRN | Acute | Anomic | 73.7 | 83.9 | 41.2 | 42.7** |
| SHT | Acute | Anomic | 43.3 | 71.0 | 0.0 | 71.0** |
| WWS | Acute | Anomic | 66.3 | 100.0 | 23.5 | 76.5** |
| WBR | Acute | Wernicke’s | 36.1 | 74.2 | 17.7 | 56.6** |
| DJN | Acute | Conduction | 47.0 | 58.1 | 0.0 | 58.1** |
| CHH | Acute | Transcortical Motor | 50.7 | 96.8 | 23.5 | 73.2** |
| GWR | Acute | Broca’s | 73.1 | 90.3 | 5.9 | 84.4** |
| CCE | Chronic | Anomic | 70.2 | 90.3 | 47.1 | 43.3** |
| LPL | Chronic | Anomic | 57.7 | 83.9 | 11.8 | 72.1** |
| JZZ | Chronic | Wernicke’s | 24.1 | 22.6 | 0.0 | 22.6* |
| MW | Chronic | Wernicke’s | 61.0 | 58.1 | 5.9 | 52.2** |
| DOL | Chronic | Broca’s | 55.5 | 38.7 | 0.0 | 38.7** |
| MH | Chronic | Broca’s | 54.2 | 45.2 | 5.9 | 39.3** |
| CAM | Chronic | Broca’s | 89.7 | 100.0 | 58.8 | 41.2** |
| TG | Chronic | Broca’s | 39.6 | 48.4 | 0.0 | 48.4** |
| SA | Chronic | Broca’s | 82.1 | 71.0 | 11.8 | 59.2** |
| LBK | Chronic | Broca’s | 75.3 | 77.4 | 11.8 | 65.7** |
| DPE | Chronic | Broca’s | 69.8 | 93.6 | 0.0 | 93.6** |
| YBN | Chronic | Broca’s | 74.2 | 100.0 | 0.0 | 100.0** |
| GDS | Chronic | Global | 88.0 | 96.8 | 29.4 | 67.4** |
| KBN | Acute | Broca’s | 41.6 | 29.0 | 100.0 | −71.0** |
| JH | Chronic | Anomic | 96.8 | 77.4 | 100.0 | −22.6* |
| AWR | Chronic | Broca’s | 83.5 | 45.2 | 88.2 | −43.1** |
| VCLM | Chronic | Broca’s | 49.3 | 25.8 | 58.8 | −33.0* |
p < 0.05,
p < 0.01 by Fisher’s exact test.
MorGen refers to the individual’s overall performance on the assessment (overall % correct). Individuals demonstrating the possessive-preserved pattern are bolded. Variants of primary progressive aphasia (PPA) include semantic variant (svPPA), logopenic variant (lvPPA), and non-fluent agrammatic variant (navPPA). Those who showed characteristics of multiple subtypes resulting in unclear classification at the time of testing are labeled with “unclassifiable PPA.” Aphasia variants for post-stroke participants are listed by the aphasia subtype established most closely to the administration of the MorGen using the Western Aphasia Battery.